John Simmons

Company: Natera

Job title: Global Vice President, Biopharma

Seminars:

Identifying High-Risk Populations for Adjuvant Trials Using ctDNA MRD 11:45 am

• Use of molecular residual disease (MRD) for patient stratification or enrichment • How real-world data can inform clinical feasibility assessments and clinical trial design • How monitoring of on-treatment ctDNA dynamics and supports early prediction of therapy efficacyRead more

day: Day One